VivaQuant

St. Paul, Minnesota, United States All United States companies → — Founded 2009

Specialty-Focused AI Wearables / RPM

Cardiology

Cardiology AI Wearables & Remote Monitoring (RPM)

Seed/Grant Funded — $3 million

Claim this company

Products

RX-1 Rhythm Express Remote Cardiac Monitoring System

VivaQuant

Cardiology AI

The RX-1 Rhythm Express Remote Cardiac Monitoring System by VivaQuant is an FDA-cleared, patch-style wearable device offering continuous ECG monitoring in MCT, Event, and Holter modes. It utilizes proprietary MDSP™ technology for superior noise suppression and accurate arrhythmia detection, providing near real-time data transmission to a cloud platform for physician review.

Available via subscription, fee-for-service, or split-bill models.

See all 1 product →

About VivaQuant

VivaQuant is a digital health company at the forefront of remote cardiac monitoring, leveraging proprietary artificial intelligence and advanced signal processing to enhance diagnostic accuracy and efficiency. For physicians, the company offers solutions for quantitative analysis of electrocardiograms (ECGs) in both biomedical and drug safety research, as well as clinical applications. Their core technology, Multi-Domain Signal Processing (MDSP™), is designed to eliminate up to 95% of noise from ambulatory ECGs while preserving signal fidelity, enabling highly sensitive and accurate measurements even in challenging conditions.

The company’s flagship product, the Rhythm Express RX-1 mini, is an FDA-cleared, small, one-piece wearable device that provides continuous cardiac monitoring. It utilizes on-board AI algorithms and patented wavelet-based analytics to quickly and accurately identify various arrhythmias, including premature ventricular contractions (PVC) and atrial fibrillation. The device transmits data to the cloud via a built-in cellular connection, where skilled staff in a US-based monitoring center review the information and report clinically significant findings to the patient’s physician. This integrated approach aims to deliver faster, higher-quality diagnoses at a reduced cost, improving patient care and streamlining clinical workflows.

Focus Areas

Remote Cardiac Monitoring ECG Analysis Arrhythmia Detection Cardiac Safety Assessment Digital Health Wearable Technology

Business Intelligence

Key Investors	National Institutes of Health (NIH), Friends and Family
Partnerships	Data Sciences International (DSI), FDA, Vizient
Technology	MDSP™ (Multi-Domain Signal Processing) technology, Wavelet-based analytics, Embedded Artificial Intelligence, Noise-cancelling algorithms, Cloud-native, Cellular connectivity
FDA Clearances	1 cleared products (estimated)

What Physicians Need to Know

Remote Cardiac Monitoring

VivaQuant's Rhythm Express RX-1 mini is a compact, one-piece mobile cardiac telemetry (MCT) device that continuously monitors ECGs during a patient's daily activities. It functions as an MCT, event recorder, or Holter monitor, transmitting data to the cloud via a built-in cellular connection. A US-based monitoring center provides 24/7/365 oversight, translating millions of heartbeats into actionable diagnostic information.

ECG Analysis

Leveraging patented MultiDomain Signal Processing (MDSPu2122) wavelet-based analytics, VivaQuant's technology removes up to 95% of noise from ambulatory ECGs without distorting morphology. This significantly improves ECG clarity, arrhythmia detection accuracy, and reduces variability in cardiac interval measurements. Their Rhythm Express software also provides automated QT interval measurements.

Arrhythmia Detection

The RX-1 mini, powered by embedded artificial intelligence and wavelet-based analytics, quickly and accurately detects over ten common arrhythmias, including atrial fibrillation, atrial flutter, premature ventricular contractions, bradycardia, tachycardia, pauses, SVEs, VT, and SVT. The high-clarity ECGs produced by MDSPu2122 technology enable near-perfect identification of these cardiac events.

Cardiac Safety Assessment

VivaQuant offers ECG research services to the pharmaceutical and medical device industries for cardiac safety and efficacy assessment. Their MDSPu2122 technology has been shown to improve the accuracy of cardiac safety assessment markers, with fully automated QT measurements improving the accuracy of concentration effect models by 22%. VivaQuant has also collaborated with the FDA to research ways to improve drug cardiac safety assessment.

Digital Health

As a digital health company, VivaQuant provides remote cardiac monitoring services under its Rhythm Express brand. Their Rhythm Accessu2122 Portal offers a seamless and intuitive experience for managing cardiac monitoring workflows, compatible with iOS and Android. The AE-1010 software is also available via a cloud-based subscription.

Wearable Technology

The RX-1 mini is designed for patient comfort and ease of use, being small, one-piece, and waterproof, allowing it to be worn in the shower. It uses standard, inexpensive electrodes and offers a battery life of typically 5 days on a single charge. This patient-centric design aims to improve compliance and provide accurate diagnostic data.

Physician Tip

For physicians, VivaQuant stands out by offering a path to **faster, higher-quality diagnoses at a lower cost** due to the superb ECG clarity and powerful arrhythmia detection enabled by their patented MDSPu2122 technology. The system provides **actionable insights** through 24/7/365 oversight by skilled staff, translating complex data into clinically relevant information. The **streamlined workflow** is supported by an easy-to-use, patient-friendly wearable device (RX-1 mini) and the intuitive Rhythm Accessu2122 Portal, which offers instant report access, electronic signature integration, and effortless patient management. High **patient compliance** is encouraged by the device's small size, comfort, waterproof design, and use of standard electrodes. Furthermore, VivaQuant's expertise in **cardiac safety assessment** and collaboration with the FDA provide a robust solution for drug and device evaluation.

VivaQuant's Rhythm Express platform, including the RX-1 mini device and Rhythm Accessu2122 Portal, is designed to integrate seamlessly into existing clinical workflows. The Rhythm Accessu2122 Portal is compatible with iOS and Android devices, facilitating easy management of patient data. Their ECG analysis software also supports reading various file formats commonly used in clinical and preclinical research studies, and they have agreements to support data files from systems like DSI's Ponemahu2122 and Dataquestu2122. The system's cloud-based communication and data delivery to a server allow for review by medical professionals and potential use by other compatible devices for arrhythmia analysis and reporting.

At a glance

Founded 2009

HQ St. Paul, Minnesota, United States · United States

Team size 51-200

CEO Brian Brockway

Funding Seed/Grant Funded — $3 million

FDA clearances 1 (estimated)

Products 1

Products by VivaQuant

1 product in the directory

RX-1 Rhythm Express Remote Cardiac Monitoring System

VivaQuant

Cardiology AI

Available via subscription, fee-for-service, or split-bill models.

Reviews & Opinions

No web reviews on file yet for VivaQuant. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about VivaQuant.

Loading videos...

Videos load interactively. If none appear, search YouTube for VivaQuant →

View all on YouTube

Press & Coverage

MTEC (Medical Technology Enterprise Consortium)

VivaQuant Receives FDA 510(k) Clearance for RX-1

VivaQuant's RX-1 device received FDA 510(k) clearance, establishing it as a reliable and advanced tool for cardiac arrhythmia detection. This clearance confirms its safety and effectiveness for cardiac monitoring.

2019-04

Medical Product Outsourcing

FDA Clears VivaQuant's RX-1 Wearable Rhythm Express Arrhythmia Device

VivaQuant, a digital health company, received FDA clearance for its RX-1 wearable device, which continuously monitors ECGs, identifies arrhythmias, and communicates data to the cloud using a built-in cellular connection. The device utilizes patented wavelet-based analytics and embedded artificial intelligence for accurate and efficient data extraction.

2019-04

EIN Presswire

VivaQuant, Inc. Named Finalist for 2021 Tekne Awards - Rhythm Express

VivaQuant was recognized as a finalist for the 2021 Tekne Awards in the Medical Technology innovation category for its RX-1 mini wearable arrhythmia monitor, highlighting its leadership in medical technology.

2021-10

Business Wire

VivaQuant Introduces Smallest One-Piece Mobile Cardiac Telemetry Device

VivaQuant launched the RX-1 mini, touted as the smallest one-piece mobile cardiac telemetry device on the market, setting a new standard for patient comfort and ease of use. The device continuously analyzes ECGs and uses AI and patented wavelet-based analytics to identify arrhythmias.

2021-01

MNSBIR

Once Again, VivaQuant Recognized by Inc. Magazine as One of the Fastest Growing Private Companies in America

VivaQuant was recognized by Inc. Magazine as one of the fastest-growing private companies in America for the second consecutive year. This recognition highlights its innovative mobile cardiac telemetry device, the RX-1 mini, and its significant revenue growth.

2024-09

Rhythm Express (VivaQuant Company News)

VivaQuant Inks Collaboration with FDA to Improve Accuracy of Drug Cardiac Safety Assessment

VivaQuant entered a five-year collaboration with the FDA to research ways to improve the cardiac safety assessment of medications. This collaboration aims to enhance the understanding of ECG cardiac safety signatures and test new methodologies.

2018-10

EIN Presswire

VivaQuant Technology Shows Promise for Improving Drug Safety Assessment Accuracy

A manuscript published in The Journal of Pharmacological and Toxicological Methods highlighted VivaQuant's MDSPu2122 technology for its ability to significantly reduce noise in ECG leads, improving the accuracy of information derived for drug safety assessment.

2018-06

Clinical Pharmacology and Therapeutics

VivaQuant Rhythm Express software demonstrates improved accuracy of cardiac safety assessment markers

A study published in Clinical Pharmacology and Therapeutics demonstrated that VivaQuant's Rhythm Express software improved the accuracy of cardiac safety assessment markers by 22 percent through automated QT measurements.

2017-11

Frequently Asked Questions

What remote cardiac monitoring products and services does VivaQuant offer for physicians and healthcare administrators?

VivaQuant offers the Rhythm Express RX-1 mini, a small, wearable device for remote cardiac monitoring that functions as a mobile cardiac telemetry (MCT) device, event recorder, or Holter monitor. This device, along with their Rhythm Express software, provides comprehensive ECG analysis services for arrhythmia detection and cardiac safety assessment.

How does VivaQuant ensure the accuracy and reliability of its ECG analysis and arrhythmia detection?

VivaQuant utilizes its patented Multi-Domain Signal Processing (MDSPu2122) technology, which is designed to remove up to 95% of noise and artifacts from ambulatory ECGs while preserving signal fidelity. This technology, combined with embedded artificial intelligence, significantly improves the accuracy of arrhythmia detection and cardiac interval measurements, leading to clearer diagnostic information.

What regulatory clearances and compliance standards does VivaQuant adhere to for its digital health and wearable technologies?

VivaQuant's RX-1 and RX-1 mini wearable cardiac monitors have received FDA 510(k) clearance, indicating they are safe and effective for their intended use. The company also operates under an FDA QSR-compliant quality system for product development.

What is VivaQuant's business model and pricing structure for healthcare providers?

VivaQuant primarily offers remote cardiac monitoring services to clinics and hospitals through a 'partnering (client bill) model,' where they provide review and reporting services from their US-based monitoring center. Their Rhythm Express software is also available for licensing under a SaaS cloud-based subscription.

What kind of support and data access can physicians and administrators expect from VivaQuant's monitoring services?

Physicians and administrators can expect 24/7/365 oversight of incoming patient data from a US-based monitoring center, where skilled staff review ECGs and report clinically important findings. The Rhythm Express platform, including the Rhythm Access Portalu2122, is designed to provide timely and actionable diagnostic information.

Does VivaQuant engage in partnerships, and what is the company's stability and growth trajectory?

VivaQuant has established partnerships, including collaborations with the FDA to improve drug cardiac safety assessment and with companies like Data Sciences International (DSI) and HeartHero for ECG analysis and embedded algorithms. The company, founded in 2009, has been recognized multiple times by Inc. Magazine as one of the fastest-growing private companies in America, indicating strong growth and stability.

Related Companies

Suggest an Edit →